Skip to main content
. Author manuscript; available in PMC: 2012 Feb 1.
Published in final edited form as: Clin Cancer Res. 2011 Jan 25;17(3):483–493. doi: 10.1158/1078-0432.CCR-10-1670

Fig. 5.

Fig. 5

Effect of Src and EGFR inhibition with gemcitabine on constitutively activated STAT3. (A) BxPC3 and PANC1 tumor tissue lysates were analyzed for pSTAT3 (Ser727 and Tyr705) and total STAT3. Only the combined treatment of dasatinib and erlotinib with gemcitabine inhibits constitutively activated STAT3 in both BxPC3 and PANC1 tumor xenografts in vivo. (B) Representative examples of immunohistochemical analysis of BxPC3 and PANC1 tumor tissues of vehicle (control) and dasatinib (DTB)+erlotinib (ERL)+gemcitabine (GEM) treated, and were stained for pSTAT3 (positive staining in brown is indicated by arrows).